Multitargeted Neuroprotective Strategies of Ethyl Pyruvate: From Molecular Mechanisms to Clinical Perspectives in CNS Disorders

Ethyl pyruvate (EP), a simple aliphatic ester of pyruvic acid, is a potent neuroprotective compound with diverse properties, including anti-inflammatory, antioxidant, anti-apoptotic, and metabolic regulatory activities. Given the intricate nature of neurological disorders, the multi-target mechanism of action of EP offers significant therapeutic advantages. Preclinical studies across various models of central nervous system (CNS) injury have consistently shown that EP mitigates neuronal loss, preserves blood-brain barrier integrity, and promotes functional recovery. The therapeutic efficacy of EP is attributed to its multifaceted mechanisms of action. It modulates key signaling pathways, such as nuclear factor kappa B (NF-κB) and high mobility group box 1 (HMGB1), activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, and provides metabolic support. Specifically, EP suppresses neuroinflammation by preventing HMGB1 release through calcium chelation and by modulating NF-κB signaling via covalent modification of the p65 subunit and stabilization of IκB-α. Furthermore, it enhances endogenous antioxidant defenses by scavenging reactive oxygen species (ROS) and inducing Nrf2 translocation. EP also acts as a bioavailable pyruvate donor, restoring intracellular adenosine triphosphate and nicotinamide adenine dinucleotide levels under ischemic or oxidative stress conditions. Comparative studies with other pyruvate derivatives have highlighted the superior efficacy and safety of EP. Additionally, structural isosteres such as N,N-diisopropyl-2-oxopropanamide (DIPOPA) and N,N-diethyl-2-oxopropanamide (DEOPA) demonstrate even greater neuroprotective potency, primarily through enhanced NF-κB inhibition by suppressing IκB-α degradation. EP is a promising therapeutic candidate for addressing oxidative stress, inflammation, and metabolic dysregulation associated with CNS diseases. However, further research is necessary to optimize the appropriate dosage, evaluate its long-term efficacy, and facilitate its clinical translation.

Authors

Institutions

Publication Details

Journal
Biomolecules & Therapeutics
Published
2026-06-30
DOI
https://doi.org/10.4062/biomolther.2025.259
Primary Topic
Biochemical Acid Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multitargeted Neuroprotective Strategies of Ethyl Pyruvate: From Molecular Mechanisms to Clinical Perspectives in CNS Disorders

S Y Kim, H S Kim
Biomolecules & Therapeutics
Biochemical Acid Research Studies
article

Multitargeted Neuroprotective Strategies of Ethyl Pyruvate: From Molecular Mechanisms to Clinical Perspectives in CNS Disorders

S Y Kim, H S Kim
article en

Abstract

Ethyl pyruvate (EP), a simple aliphatic ester of pyruvic acid, is a potent neuroprotective compound with diverse properties, including anti-inflammatory, antioxidant, anti-apoptotic, and metabolic regulatory activities. Given the intricate nature of neurological disorders, the multi-target mechanism of action of EP offers significant therapeutic advantages. Preclinical studies across various models of central nervous system (CNS) injury have consistently shown that EP mitigates neuronal loss, preserves blood-brain barrier integrity, and promotes functional recovery. The therapeutic efficacy of EP is attributed to its multifaceted mechanisms of action. It modulates key signaling pathways, such as nuclear factor kappa B (NF-κB) and high mobility group box 1 (HMGB1), activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, and provides metabolic support. Specifically, EP suppresses neuroinflammation by preventing HMGB1 release through calcium chelation and by modulating NF-κB signaling via covalent modification of the p65 subunit and stabilization of IκB-α. Furthermore, it enhances endogenous antioxidant defenses by scavenging reactive oxygen species (ROS) and inducing Nrf2 translocation. EP also acts as a bioavailable pyruvate donor, restoring intracellular adenosine triphosphate and nicotinamide adenine dinucleotide levels under ischemic or oxidative stress conditions. Comparative studies with other pyruvate derivatives have highlighted the superior efficacy and safety of EP. Additionally, structural isosteres such as N,N-diisopropyl-2-oxopropanamide (DIPOPA) and N,N-diethyl-2-oxopropanamide (DEOPA) demonstrate even greater neuroprotective potency, primarily through enhanced NF-κB inhibition by suppressing IκB-α degradation. EP is a promising therapeutic candidate for addressing oxidative stress, inflammation, and metabolic dysregulation associated with CNS diseases. However, further research is necessary to optimize the appropriate dosage, evaluate its long-term efficacy, and facilitate its clinical translation.

Biomolecules & TherapeuticsVol. 34(4)
Inha University (KR)
Openalex Percentile: Top 10%
Biochemical Acid Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Multitargeted Neuroprotective Strategies of Ethyl Pyruvate: From Molecular Mechanisms to Clinical Perspectives in CNS Disorders — S Y Kim, H S Kim · Biomolecules & Therapeutics (2026) | TGRS Research Map | TGRS